Amgen Inc
Change company Symbol lookup
Select an option...
AMGN Amgen Inc
AMSC American Superconductor Corp
CVBF CVB Financial Corp
PHG Koninklijke Philips NV
IVR Invesco Mortgage Capital Inc
CORE Core-Mark Holding Company Inc
ATMH All Things Mobile Analytic Inc
INCT Incapta Inc
BML-J Bank of America Corp
PEP PepsiCo Inc

Health Care : Biotechnology | Large Cap Value
Company profile

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Closing Price
Day's Change
3.83 (1.58%)
B/A Size
Day's High
Day's Low
(Above Average)

10-day average volume:

Kimberly-Clark shares rise after earnings blow past expectations, share repurchase program restarted

7:54 am ET July 23, 2020 (MarketWatch)

Kimberly-Clark Corp. (KMB) stock rose 2.7% in Thursday premarket trading after the Kleenex parent reported second-quarter earnings that blew past the FactSet forecast. Net income totaled $681 million, or $1.99 per share, up from $485 million, or $1.40 per share, last year. Adjusted EPS hit a record $2.20, blowing past the FactSet consensus for $1.80. Sales of $4.61 billion rose slightly from $4.59 billion last year and beat the FactSet consensus for $4.46 billion. Consumer tissue sales rose 12% to $1.6 billion. Kimberly-Clark will restart its share repurchase program after suspending it in April due to the coronavirus pandemic. It expects share repurchases to total $700 million to $900 million for the year. The company has also given full-year 2020 guidance after withdrawing it in April. It now expects net sales to rise 1% to 2%, and adjusted EPS of $7.40 to $7.60. The FactSet consensus is for sales of $18.61 billion, up 0.9% from last year, and EPS of $7.55. Kimberly-Clark stock has gained nearly 5% for the year to date while the S&P 500 index is up 1.4% for the period.

-Tonya Garcia; 415-439-6400;

(END) Dow Jones Newswires

July 23, 2020 07:54 ET (11:54 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.